Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00844376 · ClinicalTrials.gov registry record · Phase 4
Bioavailability Study for New Atorvastatin Formulation
A Phase 4 study, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
- Completed
- Registry status
- Phase 4
- Development phase
- 12
- Enrollment target
NCT00844376 is a Phase 4 study that has completed, run by Pfizer's Upjohn has merged with Mylan to form Viatris. The registered enrollment target is 12 participants.
The verdict
NCT00844376, a Phase 4 study, has completed, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 12 participants
- Enrollment target
Study Summary
The purpose of this study is to estimate the relative bioavailability of the commercial tablet with one prototype extemporaneous preparation suspension formulation, to assist with internal decision making on formulation development.
Interventions
- DRUG Lipitor
- DRUG Atorvastatin suspension
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2008-02 |
| Est. Completion | 2008-03 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00844376
The ClinicalTrials.gov registry entry for NCT00844376 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer's Upjohn has merged with Mylan to form Viatris, which has 158 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Lipitor is the first listed.
NCT00844376 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00844376 about?
NCT00844376 is a clinical study titled "Bioavailability Study for New Atorvastatin Formulation". The purpose of this study is to estimate the relative bioavailability of the commercial tablet with one prototype extemporaneous preparation suspension formulation, to assist with internal decision making on formulation development.
What is the current status of trial NCT00844376?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 12 participants. The study started on 2008-02. Estimated completion is 2008-03.
What interventions are being tested in trial NCT00844376?
The interventions under investigation include: Lipitor (DRUG), Atorvastatin suspension (DRUG).
Who is sponsoring clinical trial NCT00844376?
This trial is sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris, which has 158 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.